Abortive lytic Epstein–Barr virus replication in tonsil-B lymphocytes in infectious mononucleosis and a subset of the chronic fatigue syndrome

References

• Lerner AM, Beqaj SH, Fitzgerald JT, Gill K, Gill C, Edington J. Subset-directed antiviral treatment of 142 herpesvirus patients with chronic fatigue syndrome. Virus Adaptation and Treatment. 2010;2:47–57.
   Google Scholar
• Lerner AM, Ariza ME, Williams M, et al. Antibody to Epstein-Barr Virus deoxyuridine triphosphate nucleotidohydrolase and deoxyribonucleotide polymerase in a chronic fatigue syndrome subset. PLoS One. 2012. In press.
   Web of Science ®Google Scholar
• Rickinson AB, Epstein MA, Crawford DH. Absence of infectious Epstein-Barr virus in blood in acute infectious mononucleosis. Nature. 1975;258(5532):236.
   Web of Science ®Google Scholar
• Lerner AM, Lawrie C, Dworkin HS. Repetitively negative changing T waves at 24-h electrocardiographic monitors in patients with the chronic fatigue syndrome. Left ventricular dysfunction in a cohort. Chest. 1993;104(5):1417–1421.
   Google Scholar
• Dworkin HJ, Lawrie C, Bohdiewicz P, Lerner AM. Abnormal left ventricular myocardial dynamics in eleven patients with chronic fatigue syndrome. Clin Nucl Med. 1994;19(8):675–677.
   PubMed Web of Science ®Google Scholar
• Lerner AM, Zervos M, Dworkin HJ, et al. New Cardiomyopathy: pilot study of intravenous ganciclovir in a subset of the chronic fatigue syndrome. Infect Dis Clin Pract (Baltim Md). 1997;6(2):110–117.
   Web of Science ®Google Scholar
• Lerner AM, Dworkin HJ, Sayyed T, et al. Prevalence of abnormal cardiac wall motion in the cardiomyopathy associated with incomplete multiplication of Epstein-barr Virus and/or cytomegalovirus in patients with chronic fatigue syndrome. In Vivo. 2004;18(4):417–424.
   Web of Science ®Google Scholar
• Kogelnik AM, Loomis K, Hoegh-Petersen M, Rosso F, Hischier C, Montoya JG. Use of valganciclovir in patients with elevated antibody titers against Human Herpesvirus-6 (HHV-6) and Epstein-Barr virus (EBV) who were experiencing central nervous system dysfunction including long-standing fatigue. J Clin Virol. 2006;37 Suppl 1: S33-S38.
   Google Scholar
• Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med. 1994;121(12):953–959.
   PubMed Web of Science ®Google Scholar
• Carruthers B, Jain A, DeMeirleir K, et al. Myalgic encephalomyelitis/ chronic fatigue syndrome; clinical working case definition, diagnostic and treatment protocols. J Chronic Fatigue Syndr. 2003;11:7–115.
   Google Scholar
• Stent GS. Prematurity and uniqueness in scientific discovery. Scientific American. 1972;227(6):84–93.
   PubMed Web of Science ®Google Scholar
• Lerner AM, Beqaj SH, Gill K, Edington J, Fitzgerald JT, Deeter RG. An update on the management of glandular fever (infectious mononucleosis) and its sequelae caused by Epstein-Barr virus (HHV-4): new and emerging treatment strategies. Virus Adaptation and Treatment. 2010;2:135–145.
   Google Scholar
• Lerner AM, Beqaj SH, Deeter RG, et al. A six-month trial of valacyclovir in the Epstein-Barr virus subset of chronic fatigue syndrome: improvement in left ventricular function. Drugs Today (Barc). 2002;38(8):549–561.
   Web of Science ®Google Scholar
• Lerner AM, Beqaj SH, Deeter RG, Fitzgerald JT. Valacyclovir treatment in Epstein-Barr virus subset chronic fatigue syndrome: thirty-six months follow-up. In Vivo. 2007;21(5):707–713.
   Web of Science ®Google Scholar
• Jason LA, Richman JA, Rademaker AW, et al. A community-based study of chronic fatigue syndrome. Arch Inter Med. 1999;159(18):2129–2137.
   PubMed Web of Science ®Google Scholar
• Jason LA, Benton MC, Valentine L, Johnson A, Torres-Harding S. The economic impact of ME/CFS: individual and societal costs. Dyn Med. 2008;7:6.
   PubMedGoogle Scholar
• Kieff E, Johannsen E, Calderwood M.. Latent Epstein-Barr virus infections. In: Robertson E, editor. Epstein-Barr Virus, Latency and Transformation. Norfolk, UK: Caister Academic Press; 2010:1–24.
   Google Scholar
• Hochberg D, Middeldorp JM, Catalina M, Sullivan JL, Luzuriaga K, Thorley-Lawson DA. Demonstration of the Burkitt’s lymphoma Epstein-Barr virus phenotype in dividing latently infected memory cells in vivo. Proc Natl Acad Sci U S A. 2004;101(1):239–244.
   Web of Science ®Google Scholar
• Thorley-Lawson DA, Gross A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. New Engl J Med. 2004;350(13):1328–1337.
   PubMed Web of Science ®Google Scholar
• Kaye KM, Izumi KM, Kieff E. Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc Natl Acad Sci U S A. 1993;90(19):9150–9154.
   Web of Science ®Google Scholar
• Clemens MJ. Epstein-Barr virus: inhibition of apoptosis as a mechanism of cell transformation. Int J Biochem Cell Biol. 2006;38(2):164–169.
   Web of Science ®Google Scholar
• Greenspan JS, Greenspan D, Lennette ET, et al. Replication of Epstein- Barr virus within the epithelial cells of oral “hairy” leukoplakia, an AIDS-associated lesion. New Engl J Med. 1985;313(25):1564–1571.
   Web of Science ®Google Scholar
• Shibata D, Weiss LM. Epstein-Barr virus-associated gastric adenocarcinoma. Am J Pathol. 1992;140(4):769–774.
   PubMed Web of Science ®Google Scholar
• Cohen J. Epstein-Barr virus infections including infectious mononucleosis. In: Braunwald E, Fauci A, Isselbacher K, et al, editors. Harrison s Principles of Internal Medicine. Boston: McGraw-Hill; 1999.
   Google Scholar
• Hochberg D, Souza T, Catalina M, Sullivan JL, Luzuriaga K, Thorley- Lawson DA. Acute infection with Epstein-Barr virus targets and overwhelms the peripheral memory B-cell compartment with resting, latently infected cells. J Virol 2004;78(10):5194–5204.
   PubMed Web of Science ®Google Scholar
• Anagnostopoulos I, Hummel M, Kreschel C, Stein H. Morphology, immunophenotype, and distribution of latently and/or productively Epstein-Barr virus-infected cells in acute infectious mononucleosis: implications for the interindividual infection route of Epstein-Barr virus. Blood. 1995;85(3):744–750.
   Web of Science ®Google Scholar
• Miyashita EM, Yang B, Babcock GJ, Thorley-Lawson DA. Identification of the site of Epstein-Barr virus persistence in vivo as a resting B cell. J Virol. 1997;71(7):4882–4891.
   Web of Science ®Google Scholar
• Liu YJ, Arpin C. Germinal center development. Immunol Rev. 1997;156:111–126.
   PubMed Web of Science ®Google Scholar
• Tough DF, Sprent J. Lifespan of lymphocytes. Immunol Res. 1995;14(1):1–12.
   Google Scholar
• Babcock GJ, Decker LL, Freeman RB, Thorley-Lawson DA. Epstein-Barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients. J Exp Med. 1999;190(4):567–576.
   Web of Science ®Google Scholar
• Yao QY, Ogan P, Rowe M, Wood M, Rickinson AB. Epstein-Barr virus-infected B cells persist in the circulation of acyclovir-treated virus carriers. Int J Cancer Suppl. 1989;43(1):67–71.
   Google Scholar
• Babcock GJ, Decker LL, Volk M, Thorley-Lawson DA. EBV persistence in memory B cells in vivo. Immunity. 1998;9(3):395–404.
   PubMed Web of Science ®Google Scholar
• Thorley-Lawson DA. Epstein-Barr virus: exploiting the immune system. Nat Rev Immunol. 2001;1(1):75–82.
   PubMed Web of Science ®Google Scholar
• Tanner J, Weis J, Fearon D, Whang Y, Kieff E. Epstein-Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis. Cell. 1987;50(2):203–213.
   Web of Science ®Google Scholar
• Hadinoto V, Shapiro M, Sun CC, Thorley-Lawson DA. The dynamics of EBV shedding implicate a central role for epithelial cells in amplifying viral output. PLoS Pathog. 2009;5(7):e1000496.
   PubMed Web of Science ®Google Scholar
• Sixbey JW, Nedrud JG, Raab-Traub N, Hanes RA, Pagano JS. Epstein-Barr virus replication in oropharyngeal epithelial cells. New Engl J Med. 1984;310(19):1225–1230.
   Web of Science ®Google Scholar
• Laichalk LL, Thorley-Lawson DA. Terminal differentiation into plasma cells initiates the replicative cycle of Epstein-Barr virus in vivo. J Virol 2005;79(2):1296–1307.
   PubMed Web of Science ®Google Scholar
• Perry M, Whyte A. Immunology of the tonsils. Immunol Today. 1998;19(9):414–421.
   Google Scholar
• Lerner AM, Beqaj SH. A paradigm linking herpesvirus immediate- early gene expression apoptosis and myalgic encephalomyelitis chronic fatigue syndrome. Virus Adaptation and Treatment. 2011;3:19–24.
   Google Scholar
• Jones JF, Ray CG, Minnich LL, Hicks MJ, Kibler R, Lucas DO. Evidence for active Epstein-Barr virus infection in patients with persistent, unexplained illnesses: elevated anti-early antigen antibodies. Ann Intern Med. 1985;102(1):1–7.
   PubMed Web of Science ®Google Scholar
• Patnaik M, Komaroff AL, Conley E, Ojo-Amaize EA, Peter JB. Prevalence of IgM antibodies to human herpesvirus 6 early antigen (p41/38) in patients with chronic fatigue syndrome. J Infect Dis. 1995;172(5):1364–1367.
   Web of Science ®Google Scholar
• Sairenji T, Yamanishi K, Tachibana Y, Bertoni G, Kurata T. Antibody responses to Epstein-Barr virus, human herpesvirus 6 and human herpesvirus 7 in patients with chronic fatigue syndrome. Intervirology. 1995;38(5):269–273.
   Web of Science ®Google Scholar
• Straus SE, Tosato G, Armstrong G, et al. Persisting illness and fatigue in adults with evidence of Epstein-Barr virus infection. Ann Intern Med. 1985;102(1):7–16.
   PubMed Web of Science ®Google Scholar
• Tynell E, Aurelius E, Brandell A, et al. Acyclovir and prednisolone treatment of acute infectious mononucleosis: a multicenter, doubleblind, placebo-controlled study. J Infect Dis. 1996;174(2):324–331.
   PubMed Web of Science ®Google Scholar
• van der Horst C, Joncas J, Ahronheim G, et al. Lack of effect of peroral acyclovir for the treatment of acute infectious mononucleosis. J Infect Dis. 1991;164(4):788–792.
   PubMed Web of Science ®Google Scholar
• Buchwald D, Ashley RL, Pearlman T, Kith P, Komaroff AL. Viral serologies in patients with chronic fatigue and chronic fatigue syndrome. J Med Virol 1996;50(1):25–30.
   PubMed Web of Science ®Google Scholar
• Buchwald D, Sullivan JL, Komaroff AL. Frequency of ‘chronic active Epstein-Barr virus infection’ in a general medical practice. JAMA. 1987;257(17):2303–2307.
   PubMed Web of Science ®Google Scholar
• Di Luca D, Zorzenon M, Mirandola P, Colle R, Botta GA, Cassai E. Human herpesvirus 6 and human herpesvirus 7 in chronic fatigue syndrome. J Clin Microbiol. 1995;33(6):1660–1661.
   Web of Science ®Google Scholar
• Hellinger WC, Smith TF, Van Scoy RE, Spitzer PG, Forgacs P, Edson RS. Chronic fatigue syndrome and the diagnostic utility of antibody to Epstein-Barr virus early antigen. JAMA. 1988;260(7):971–973.
   PubMed Web of Science ®Google Scholar
• Hickie I, Davenport T, Wakefield D, et al. Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study. BMJ. 2006;333(7568):575.
   PubMed Web of Science ®Google Scholar
• Holmes GP, Kaplan JE, Stewart JA, Hunt B, Pinsky PF, Schonberger LB. A cluster of patients with a chronic mononucleosis-like syndrome. Is Epstein-Barr virus the cause? JAMA. 1987;257(17):2297–2302.
   PubMed Web of Science ®Google Scholar
• Straus SE, Dale JK, Tobi M, et al. Acyclovir treatment of the chronic fatigue syndrome. Lack of efficacy in a placebo-controlled trial. New Engl J Med. 1988;319(26):1692–1698.
   PubMed Web of Science ®Google Scholar
• Glaser R, Litsky ML, Padgett DA, et al. EBV-encoded dUTPase induces immune dysregulation: implications for the pathophysiology of EBV- associated disease. Virology. 2006;346(1):205–218.
   Web of Science ®Google Scholar
• Glaser R, Padgett DA, Litsky ML, et al. Stress-associated changes in the steady-state expression of latent Epstein-Barr virus: implications for chronic fatigue syndrome and cancer. Brain Behav Immun. 2005;19(2):91–103.
   PubMed Web of Science ®Google Scholar
• Lerner AM, Beqaj SH, Deeter RG, Fitzgerald JT. IgM serum antibodies to Epstein-Barr virus are uniquely present in a subset of patients with the chronic fatigue syndrome. In Vivo. 2004;18(2):101–106.
   Web of Science ®Google Scholar
• Miller RL, Glaser R, Rapp F. Studies of an Epstein-Barr virus-induced DNA polymerase. Virology. 1977;76(2):494–502.
   Web of Science ®Google Scholar
• Jones JF, Williams M, Schooley RT, Robinson C, Glaser R. Antibodies to Epstein-Barr virus-specific DNase and DNA polymerase in the chronic fatigue syndrome. Arch Inter Med. 1988;148(9):1957–1960.
   Google Scholar
• Liu MY, Chou WH, Nutter L, Hsu MM, Chen JY, Yang CS. Antibody against Epstein-Barr virus DNA polymerase activity in sera of patients with nasopharyngeal carcinoma. J Med Virol. 1989;28(2):101–105.
   Web of Science ®Google Scholar
• Natelson BH, Ye N, Moul DE, et al. High titers of anti-Epstein-Barr virus DNA polymerase are found in patients with severe fatiguing illness. J Med Virol. 1994;42(1):42–46.
   Web of Science ®Google Scholar
• Lin Z, Flemington EK.. Regulation of EBV latency by viral lytic proteins. In: Robertson E, editor. Epstein-Barr Virus: Latency and Transformation. Norfolk, UK: Caister Academic Press; 2010:167–192.
   Google Scholar
• Klimas NG, Koneru AO. Chronic fatigue syndrome: inflammation, immune function, and neuroendocrine interactions. Curr Rheumatol Rep. 2007;9(6):482–487.
   PubMedGoogle Scholar
• Efstathiou S, Ho YM, Hall S, Styles CJ, Scott SD, Gompels UA. Murine herpesvirus 68 is genetically related to the gammaherpesviruses Epstein-Barr virus and herpesvirus saimiri. J Gen Virol. 1990;71(Pt 6):1365–1372.
   Google Scholar
• Sunil-Chandra NP, Efstathiou S, Nash AA. Murine gammaherpesvirus 68 establishes a latent infection in mouse B lymphocytes in vivo. J GenVirol 1992;73(Pt 12):3275–3279.
   Google Scholar